NRBO - NeuroBo Pharmaceuticals Inc. Looks to Continue to Trade Below its Annual-Low Share Price Today

Shares of NeuroBo Pharmaceuticals Inc. (NASDAQ:NRBO) traded today at $3.20, breaking its 52-week low. So far today approximately 1.1 million shares have been exchanged, as compared to an average 30-day volume of 213,000 shares.

Potential upside of 65.6% exists for NeuroBo Pharmaceuticals Inc., based on a current level of $3.36 and analysts' average consensus price target of $5.56.

NeuroBo Pharmaceuticals Inc. share prices have moved between a 52-week high of $29.49 and the current low of $3.20 and are currently at $3.36 per share.

NeuroBo Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in developing and commercializing therapies for patients with diabetic neuropathy and Alzheimer's disease. Its product candidate comprises NB-01, which is primarily focused on the development of a treatment for painful diabetic neuropathy; NB-02, which treat the symptoms of neurodegenerative diseases associated with the malfunction of a protein called tau, and with amyloid-beta plaque deposition; Gemcabene, which is focused on developing and commercializing therapies for the treatment of dyslipidemia.

Receive IBN Spotlights - "Bite Size" Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer